Driven by a paradigm shift to curative early-stage interventions and surging ADC demand, the market offers massive upside.

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Eli Lilly is reported to be eyeing a $1 billion-plus takeover of Ventyx Biosciences that, if confirmed, suggests 2026 could ...

Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions ...

The ETF's components aren't high-growth stocks, and the ETF doesn't usually beat the market. It's up 55% over the past five ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

Lower-quality stocks have historically outperformed quality in a "dash to trash" in January, according to BofA. Quality ...

Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical ...